Yahoo Finance

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for ...

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as ...
Yahoo Finance

AIM's Serum-Free Iterative Rabies Vaccine Receives Acceptance for Market Registration; Institutions Predict Significant Valuation Recovery Potential for the Company

HONG KONG, April 8, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced on April 7, 2025 that the company's research and development of the serum-free ...
manilatimes

World's First Serum-Free Iterative Rabies Vaccine from AIM Successfully Passes On-Site Registration Inspections and Is Imminent for Launch

HONG KONG, Feb. 6, 2026 /PRNewswire/ -- Poised to Fill the Global Market Gap, the Serum-Free Iterative Rabies Vaccine Approaches a Critical Milestone in Commercialization. AIM Vaccine (06660.HK), a ...
Seeking Alpha

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for ...

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The ...